Printer Friendly
The Free Library
5,670,285 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Pyrosequencing Strengthens Intellectual Property for Core Technology With Two New U.S. Patents Issued.


Business Editors

UPPSALA, Sweden--(BUSINESS WIRE)--Aug. 28, 2001

Pyrosequencing AB (OMX OMX Office Max (stock symbol) :PYROa.) a developer, manufacturer and marketer of DNA sequencing DNA sequencing

The determination of the sequence of nucleotides in a sample of DNA.
 systems for applied genetic analysis, today announced that it has been issued two additional U.S. patents covering the Company's Pyrosequencing(tm) Technology. U.S. Patent No. 6,210,891 and U.S. Patent No. 6,258,568 broadly cover methods for DNA sequencing based on the real-time detection of pyrophosphate pyrophosphate /py·ro·phos·phate/ (-fos´fat) a salt of pyrophosphoric acid.

py·ro·phos·phate
n. Abbr. PP
A salt or ester of pyrophosphoric acid.
 and improvements in the chemistry of Pyrosequencing's novel genetic analysis technology. These patents complement and enhance the Company's existing broad coverage for sequencing-by-synthesis, an automated method for determining the base sequence of either DNA DNA: see nucleic acid.
DNA
 or deoxyribonucleic acid

One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes.
 or RNA RNA: see nucleic acid.
RNA
 in full ribonucleic acid

One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic
.

"These two new patents provide further protection for our unique chemistry and sequencing systems that are the essence of Pyrosequencing(tm)," said Erik Wallden, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  and President of Pyrosequencing AB. "We now have strong coverage for our core technologies and are continuing to build value for our platform technology. In addition, we are developing new molecular diagnostic product concepts that leverage our intellectual property in cardiovascular and other therapeutic areas," he added.

U.S. Patent 6,210,891 covers methods for sequencing DNA, where the incorporation of bases (nucleotide triphosphates) is coupled to the release of pyrophosphate (PPi) and its detection via a light signal. PPi triggers a luciferin-luciferase based enzymatic cascade that produces a light pulse proportional to the amount of base incorporated. The sequencing or base incorporation reactions can be continuously monitored because the sequencing and detection are performed simultaneously as part of the same process.

The second patent (6,258,568) covers an improved DNA sequencing method that involves detecting pyrophosphate release as new nucleotides are added to a growing DNA strand and then degrading the unincorporated nucleotides through the addition of a nucleotide-degrading enzyme. In order to perform rapid and accurate sequencing without numerous wash steps, the unincorporated nucleotides must be removed before addition of the next nucleotides. The use of a nucleotide-degrading enzyme facilitates rapid, accurate and convenient sequencing without numerous wash steps. Additionally, the nucleotide-degrading enzyme switches off the light reaction and allows the next sequencing reaction to be initiated. The patent covers the removal of these excess nucleotides with enzymes, such as apyrase ap·y·rase
n.
Any of various enzymes that catalyze the hydrolysis of ATP, causing the release of phosphate and energy.
.

These new patents add to Pyrosequencing's strong intellectual property position surrounding sequencing and DNA analysis DNA analysis Any technique used to analyze genes and DNA. See Chromosome walking, DNA fingerprinting, Footprinting, In situ hybridization, Jeffries' probe, Jumping libraries, PCR, RFLP analysis, Southern blot hybridization.  technologies, which includes a broad patent issued for sequencing-by-synthesis using any detection method. The sequencing-by-synthesis patent covers methods for determining the sequence of DNA or RNA molecules by detecting the incorporation or addition of specific nucleotides into a growing strand of DNA or RNA. Nucleotides are added, like building blocks, into the growing strand if they are complementary to the unpaired nucleotide that exists in the template strand The template strand (also known as the antisense strand or the anticoding strand or the noncoding strand) is the strand of DNA that the RNA polymerase uses as a guide to build complementary mRNA. This is the reverse complement of the coding strand. . A polymerase enzyme helps add the nucleotides to this growing or newly synthesized strand of DNA or RNA and this incorporation can be detected using various methodologies.

About Pyrosequencing AB

Pyrosequencing AB develops, manufactures and sells complete solutions for applied genetic analysis based on its proprietary Pyrosequencing(tm) technology, a simple-to-use DNA sequencing technique. In the post-genome era, Pyrosequencing's technology has established the Company as one of the leading suppliers of solutions for accurate, consistent DNA analysis in research institutions and pharmaceutical, genomics and agbiotech companies.

For the analysis of single nucleotide polymorphisms (SNPs), the PSQ PSQ Political Science Quarterly (journal)
PSQ Pyrosequencing
PSQ Pipsqueak (gene)
PSQ Patient Satisfaction Questionnaire
PSQ Presidential Studies Quarterly
(tm)96 System with SNP SNP Scottish National Party

Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily
 Software and Reagent Kits is used by customers such as AstraZeneca, GlaxoSmithKline, the Harvard Center for Cancer Prevention, the National Institutes of Health (NIH "Not invented here." See digispeak.

NIH - The United States National Institutes of Health.
), the Karolinska Institute and DuPont Agriculture. The Company's Sequence Analysis Software and Reagent Kits together with the PSQ 96 System are used for the identification of gene-specific DNA sequences for applications such as bacterial and viral typing where speed and ease of use are essential.

The Company is headquartered in Uppsala, Sweden with North American operations North American operation Surgical oncology Radical surgery of a 'frozen pelvis', consisting of radical en bloc resection of the uterus and urinary bladder. See 'Frozen pelvis.'. Cf 'All-American' and 'South American' operations.  located in Westborough, Massachusetts. Pyrosequencing AB also has sales offices and distribution partners in Europe, Asia Pacific and the Middle East. Pyrosequencing AB is listed on the OM Stockholm Exchange. The Company's web address is www.pyrosequencing.com.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," and "should," among others. These forward- looking statements are based on Pyro-sequencing's current expectations. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995 provides a "safe harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
" for such forward-looking statements. In order to comply with the terms of the safe harbor, Pyrosequencing notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward- looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Pyrosequencing's products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors.

Note to Editors: This press release is also accessible online at www.Waymaker.net.

The following files are available for download: http://www.waymaker.net/bitonline/2001/08/28/20010828BIT00520/bit0001.doc http://www.waymaker.net/bitonline/2001/08/28/20010828BIT00520/bit0001.pdf
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:4EUSW
Date:Aug 28, 2001
Words:906
Previous Article:Fred's Registers Offering of 1.65 Million Common Shares.
Next Article:Andrx Announces Retirement of Chief Scientific Officer.



Related Articles
ENZO BIOCHEM GETS NEW PATENT ALLOWANCES IN U.S/CANADA.
World-Renowned Karolinska Institute Adopts Pyrosequencing Technology for Disease-Related Research; Departments Independently Purchase PSQ 96 Systems.
Pyrosequencing AB Announces First Customer in High Throughput DNA Sequencing Program Swedish Consortium for Functional Genomics Will Use PTP for SNP...
Pyrosequencing AB and Mosaic Technologies Enter Cross-License Agreement to Leverage DNA Sequencing Technologies.
Pyrosequencing Granted Patent for Diagnostics and Therapeutic Responses in Cardiovascular Disease.
Pyrosequencing AB Reports Second Quarter Results for Period Ended June 30, 2001; Installed Base Climbs to Over 100 PSQ 96 Systems for Applied...
Pyrosequencing AB Reports Third Quarter Results for Period Ended September 30, 2001; Company Makes Significant Advances in Molecular Diagnostics.
It's all mine: protect your intellectual property. (On The Shelf).(Brief Article)
Citizen-based agenda.(citizen-sponsored public health movements)(Brief Article)
454 LIFE SCIENCES GETS GENOME LICENSE FROM PYROSEQUENCING.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles